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Table 2
Grade 3/4 Non-hematologic Toxicities
Preferred Term All Grades % (N¼61) Grade 3/4 % (N¼61)
Diarrhea 93 3
Nausea 90 2
Fatigue 77 2
Hypokalemia 74 28
Vomiting 64 0
Hypophosphatemia 49 48
Decreased Appetite 49 0
Pyrexia 48 3
Constipation 48 0
Febrile Neutropenia 41 28
Mucosal Inﬂammation 38 10
Dizziness 38 0
Stomatitis 28 5
Abdominal Pain 28 0
Dysgeusia 28 0
Dyspepsia 26 0
Abstracts / Biol Blood Marrow Transplant 21 (2015) S127eS146S138implanted ports and therefore had a Vascath placed on the
morning of pheresis. Twelve patients completed pheresis
and reached target CD34 collection through double lumen
CVL. One patient was unable to complete pheresis via his
CVL and had a successful pheresis the following day after
Vascath placement. Median inlet ﬂow rates were
signiﬁcantly lower in patients undergoing pheresis with a
double lumen CVL when compared to patients undergoing
pheresis via Vascath and there was a signiﬁcantly higher
rate of pressure error readings in patients with CVLs. Time
from admission to start of pheresis was signiﬁcantly less in
patients who underwent pheresis with a CVL. There was no
signiﬁcant difference in time on machine, CD34/kg
collected, or number of days of pheresis.
Conclusion: Hematopoietic stem cell pheresis utilizing dou-
ble lumenCVL is feasiblewith the potential beneﬁts of shorter
hospitalization and avoidance of second line placement.155
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Melphalan 200 mg/m2 IV is the most common conditioning
regimen for AHCT in MM. Conventional melphalan formu-
lations (eg, Alkeran) have marginal solubility, limited
chemical stability and require PG as a co-solvent, which is
associated with renal dysfunction and arrhythmias. Captisol-
enabled Melphalan HCL (CE-Melphalan) is a PG-free formu-
lation of melphalan that incorporates Captisol, a modiﬁedTable 1
Patient Characteristics
Total (N[61)
Median Age (range) in yrs 62 (32-73)
Age ‡ 65 yrs 30%
Male Gender 57%
Race
White 80%
Black/African American 18%
Other 2%
ECOG Status
0 59%
1 38%
2 3%
Disease Status Pre-treatment
sCR 0%
CR 5%
VGPR 44%
PR 32%
Disease Status at Day 100 post-AHCT
sCR 13%
CR 8%
VGPR 61%
PR 18%cyclodextrin that improves its solubility, stability and
bioavailability. In a previous Phase 2 study, CE-Melphalan
was shown to be bioequivalent to Alkeran.
Methods: This Phase II, open-label study enrolled 61 pts with
MMwho received 200 mg/m2 of CE-Melphalan (100 mg/m2/
day x 2) followed by AHCT. Most subjects were male (57%)
with a median age of 62.0 years (range 32-73), including 56
(92%) subjects who received upfront AHCT and 5 (8%) after
relapse (Table 1). Median lines of prior therapy was 3 (range
2-16). High risk cytogenetics in 6 (10%) pts. Disease status at
pre-treatment included CR in 3 subjects, VGPR in 27 and PR
in 20 subjects.
Results: All subjects achieved myeloablation followed by
successful engraftment. Median time to neutrophil engraft-
ment was 12 days post-AHCT (range: 10-12); time to platelet
engraftment was 13 days (range 10-28). There was no mor-
tality by Day 100, and as expected the most common Grade 3
and 4 toxicities were hematologic. Non-hematologic toxic-
ities are summarized in Table 2. Severe mucositis was
reported in few patients (Grade 3/4; 10%). At Day 100 post-
AHCT, all patients (100%) had a response with 82% of subjects
achieving a>¼ VGPR response including sCR in 13%, CR in 8%
and VGPR in 61%.
Conclusions: CE-Melphalan led to successful myeloablation
and subsequent engraftment inMMpatients with nomortality
or unexpected transplant-related toxicity over conventional
melphalan. The incidence of Grade 3-4 mucositis was low.
Overall,100% of subjects responded to high doseCE-Melphalan,
and in the subgroup of high risk patients (n¼6, 10%), an
encouraging 67% VGPR or better responses were achieved.156
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In the post combination antiretroviral therapy (cART) era,
HIV infected patients are better able to tolerate chemo-
therapy for HIV-associated lymphoma and results of the
treatment are similar now to non-HIV infected patients.
Consequently the use of hematopoietic stem cell trans-
plant (HSCT) has been investigated in the post cART era.
One of the main challenges that faces clinicians though is
the potential for cART and chemotherapy drug-drug
interactions.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S127eS146 S139The aim of our study was to review toxicities related to the
continuation of cART during chemotherapy in HIV-infected
patients undergoing autologous stem cell transplants (ASCT)
for haematological malignancies.
This was a retrospective study, which included HIV-
infected patients who were on cART and underwent ASCT
for a haematological malignancy from January 1st 2003 to
December 31st 2013 at a single institution. We reviewed
adverse effects related to the use cART during conditioning
chemotherapy.
A total of 11 patients were included, n¼1 acute myeloid
leukemia (AML), n¼4 multiple myeloma (MM), n¼4 Burkitt
lymphoma, n¼1 plasmablastic lymphoma, n¼1 primary
effusion lymphoma and n¼1 Hodgkin lymphoma. Of the 11
patients, 6 (54%) were on non-Protease inhibitor (PI) and 5
(56%) were on PI based cART during their transplant. NoTRM
were observed; all patients continued cART during
conditioning chemotherapy. 6 Patients relapsed, 2 were
salvaged by allogeneic HSCT, and 2 MM patients were given
salvage treatment. There were 5 non-treatment related
deaths, n¼1 developed secondary malignancy, n¼1 relapsed
AML, n¼2 relapsed MM and one patient died due to
zidovudine induced lactic acidosis 10 months post ASCT.
Overall survival from ranged from 1-8 yrs.
This case series demonstrated that concomitant use of
cART during conditioning chemotherapy for patients
undergoing ASCT does not adversely affect treatment
outcomes. Therefore, we recommend continuing cART
during ASCT. However, we recommend avoiding zidovudine
during conditioning chemotherapy due to high risk of
myelosuppression.Figure 1. Progression free in survival among Caucasian patients compared to
African American patients during the 24-month follow-up period (Log Rank¼
0.03).157
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Background: The incidence of CMV after ASCT is much lower
(1-9%) than after allogeneic transplantation. However, with
recent use of R, there has been increasing concern about
opportunistic infections. The objective of our study was to
determine the disease burden and characteristics of CMV
infection/reactivation after ASCT in recent years.
Methods: Records were searched in Karmanos Cancer Center
database for the occurrence of CMV infection/disease during
the post-transplantation period in patients undergoing ASCT
between December 2007 and December 2013. Charts were
reviewed retrospectively to identify characteristics of CMV
infection/reactivation/disease, demographic features and
outcomes of the affected patients.
Results: Seven of 978 ASCT recipients {multiple myeloma
(MM): 601 patients (pts), non-Hodgkins lymphoma (NHL):
252 pts, Hodgkins lymphoma (HD): 99 pts} were found to be
viremic by CMV PCR within the ﬁrst 3 months after trans-
plant, during work up for antibiotic-resistant fever. The
median time for development of CMV PCR positive status
was 33 days post-transplantation (range, 18e78 days). CMV
viremia developed in 3 of the 236 patients who received R
with induction or preparative regimens as compared to 4 of
742 who did not receive R (p¼0.2). In all 7 patients, viremia
developed after neutrophil engraftment.
Of the 7 patients, 3 developed bacterial and/or fungal
infection within 60 days from onset of viremia. Median levelof CMV viremia was 16,912 copies/ml (range, 724e33,100) in
these 3 patients. All 3 patients received anti-viral and other
appropriate anti-microbial therapy. The viremia resolved in a
median of 17.5 days (range, 9e26 days). One of these patients
died at 28 days from onset of CMV viremia due to invasive
candidiasis and septic shock.
The remaining 4 patients, who did not develop bacterial
or fungal infection within 60 days from viremia, had median
CMV copies/ml of 700 (range, 250e1707). Only one of these
4 patients received anti-CMV therapy but he died shortly,
thereafter (at 19 days from onset of viremia), due to pro-
gression of primary malignancy.
None of the 7 patients had documented evidence of tissue
invasive CMV disease.
Conclusion: Despite the use of R prior to ASCT, frequency of
CMV infection/disease remains low in this population. Low
level of CMV viremia does not appear to warrant therapy.
Higher levels of viremia were associated with development
of subsequent bacterial/fungal infections.158
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Background: Upfront ASCT in eligible patients (pts) is
currently considered a standard of care and has been shown
to improve disease free survival and overall survival (OS) in
randomized trials. The incidence of MM in AA population is
twice compared to the Caucasian (C) population and the
mortality rates are higher in AA pts with MM. The plausible
reasons for this are higher incidence of poor risk disease, less
upfront exposure to novel agents, lower referral rate for ASCT
and poor access to health care. The aim of our study is to
identify differences in clinical characteristics and outcomes
in two groups.
Methods: We performed a retrospective analysis in MM pts
who underwent ASCT at Karmanos Cancer Center between
